INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10828753		
Filing Date		2004-04-21		
First Named Inventor Cla				
Art Unit		1623		
Examiner Name	McInt	tosh III		
Attorney Docket Number		60137.0002USU1		

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	ent Number Kind Code1 Issue Date Name of Patentee or Application of cited Document			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1									
If you wis	n to a	 dd additional U.S. Pate	l nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	ı to a	dd additional U.S. Publ	shed Ap	plication	n citation	n information p	lease click the Ad	d butte	on.	
				FOREI	GN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² į		Kind Code4	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	_{T6}
	1									
If you wis	n to a	⊥ dd additional Foreign P	L atent Do	cument	citation	information p	L lease click the Add	butto	n	
			NON	I-PATEI	NT LITE	RATURE DO	CUMENTS			
Examiner Initials* No Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									T 5	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

English language translation is attached.

Application Number		10828753		
Filing Date		2004-04-21		
First Named Inventor	Clark			
Art Unit		1623		
Examiner Name	McInte	osh III		
Attorney Docket Number		60137 0002USU1		

	1	Stuyver, et al., "Inhibition of hepatitis C replicon RNA synthesis by B-D-2'-deoxy-2'-fluoro-2'-C-methlcytidine: a specific inhibitor of hepatitis C virus replication," Antiviral Chemistry & Chemotherapy 17:79-87, 2006							
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button								
EXAMINER SIGNATURE									
Examiner Signature Date C				sidered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									
¹ See Kind (Codes o	of USPT	TO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued	the docume	nt. by the two-letter code (W	IPO			

Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if